8-K
filed February 14, 2023, 6:59 PM ET
ticker ADPT
CIK 0001478320
earnings
confidence high
sentiment positive
materiality 0.75
Adaptive Biotechnologies Q4 revenue $55.2M (+46% YoY); guides FY2023 rev $205M-$215M
Adaptive Biotechnologies Corp
2022-FY EPS reported
-$1.40
revenue$185,308,000
- Full year 2022 revenue $185.3M (+20% YoY); MRD revenue $87.1M (+32%), Immune Medicine $98.2M (+11%).
- clonoSEQ test volume Q4 up 54% to 10,526 tests; full year up 51% to 36,871 tests.
- Net loss Q4 $40.2M vs $61.4M; adjusted EBITDA loss $19.6M vs $44.9M YoY.
- 2023 revenue guidance $205M-$215M; operating expenses expected below $385.5M.
- Long-term targets: 20-30% revenue CAGR, positive adjusted EBITDA in 2025, cash flow breakeven in 2026.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Adaptive Biotechnologies Corp reported full year 2023 results: revenue $205 million to $215 million. Guidance initiated.
- Period
- full year 2023
- Revenue
- $205 million to $215 million
- Guidance
- initiated
- Result
- guidance update
Exact text from the filing
Adaptive Biotechnologies expects full year 2023 revenue to be in the range of $205 million to $215 million.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Adaptive Biotechnologies Corp reported full year ended December 31, 2022 results: revenue $185.3 million, net income Net loss was $200.4 million.
- Period
- full year ended December 31, 2022
- Revenue
- $185.3 million
- Net income
- Net loss was $200.4 million
- Result
- reported results
Exact text from the filing
Revenue was $185.3 million for the year ended December 31, 2022, representing a 20% increase from the prior year.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Adaptive Biotechnologies Corp reported fourth quarter ended December 31, 2022 results: revenue $55.2 million, net income Net loss was $40.2 million.
- Period
- fourth quarter ended December 31, 2022
- Revenue
- $55.2 million
- Net income
- Net loss was $40.2 million
- Result
- reported results
Exact text from the filing
Revenue was $55.2 million for the quarter ended December 31, 2022, representing a 46% increase from the fourth quarter in the prior year.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.